Home » Stocks » PRQR

ProQR Therapeutics N.V. (PRQR)

Stock Price: $7.07 USD 0.01 (0.14%)
Updated Jun 24, 2021 3:24 PM EDT - Market open
Market Cap 466.86M
Revenue (ttm) 10.98M
Net Income (ttm) -50.78M
Shares Out 66.13M
EPS (ttm) -1.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $7.07
Previous Close $7.06
Change ($) 0.01
Change (%) 0.14%
Day's Open 7.10
Day's Range 6.99 - 7.29
Day's Volume 179,781
52-Week Range 3.40 - 9.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

2 weeks ago - GlobeNewsWire

ProQR (PRQR) delivered earnings and revenue surprises of -7.14% and -92.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) --   ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

1 month ago - GlobeNewsWire

Yarrow Biotechnology Inc, a newly created company by RTW Investments LP, has in-licensed exclusive rights to ProQR Therapeutics N.V.'s (NASDAQ: PRQR) antisense oligonucleotide technology to develop and ...

1 month ago - Benzinga

With the trading day more than halfway over, the broad markets were somewhat mixed on the day.

Other stocks mentioned: COST, FDX, GOOG, GOOGL, UPS, DISH, PCG ...
1 month ago - 24/7 Wall Street

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapi...

2 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

2 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapi...

2 months ago - GlobeNewsWire

A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.

2 months ago - The Motley Fool

LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA ther...

2 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapi...

2 months ago - GlobeNewsWire

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA ther...

2 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therap...

2 months ago - GlobeNewsWire

PRQR stock is rocketing up this morning, carrying the momentum of a press release from earlier in the week. Here's what you need to know.

2 months ago - InvestorPlace

Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.

Other stocks mentioned: APOP, EVFM, FSTX, IMMP
2 months ago - Benzinga

ProQR Therapeutics NV (NASDAQ: PRQR) shares are trading higher by more than 52% after the company reported results Wednesday from its trial of QR-421a in Usher Syndrome, though the stock did not surge i...

Other stocks mentioned: APOP
2 months ago - Benzinga

The company reported positive results from a clinical trial.

3 months ago - The Motley Fool

ProQR Therapeutics NV (NASDAQ: PRQR) has announced results from a planned analysis of its Phase 1/2 Stellar trial evaluating QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa ...

3 months ago - Benzinga

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

3 months ago - GlobeNewsWire

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...

Other stocks mentioned: BMY, PFE, BCRX, MRKR, PCRX, RUBY, ZEAL
3 months ago - Benzinga

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

3 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

3 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

4 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

5 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

6 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

7 months ago - GlobeNewsWire

ProQR (PRQR) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

7 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapie...

7 months ago - GlobeNewsWire

Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally

8 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA thera...

8 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transfo...

9 months ago - GlobeNewsWire

ProQR Therapeutics: Bringing A New Cure To The Market

9 months ago - Seeking Alpha

LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transfor...

10 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therap...

11 months ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass. , July 14, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA the...

11 months ago - GlobeNewsWire

Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data Call on July 20 will include a snapshot from th...

11 months ago - GlobeNewsWire

At this stage, we have narrowed down our search to five low-beta stocks that have provided double-digit returns in the past month.

Other stocks mentioned: OOMA, SPWH, SWBI, ZS
1 year ago - Zacks Investment Research

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

Other stocks mentioned: ATXI, BJ, FRO, ICLK
1 year ago - Zacks Investment Research

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therap...

1 year ago - GlobeNewsWire

ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Leiden, Netherlands & Cambridge, Mass., May 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

1 year ago - GlobeNewsWire

ProQR (PRQR) delivered earnings and revenue surprises of 23.91% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) --  March 31, 2020 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the ...

1 year ago - GlobeNewsWire

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transfor...

1 year ago - GlobeNewsWire

My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S. My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.

1 year ago - GlobeNewsWire

Designation is for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene Designation is for the treatment of patients with retinitis pigmentosa caused by m...

1 year ago - GlobeNewsWire

ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant retinitis pigmentosa.

1 year ago - Zacks Investment Research

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medi...

1 year ago - GlobeNewsWire

ProQR Therapeutics N.V. (NASDAQ: PRQR) shares jumped early on Thursday after the firm announced that it received Orphan Drug designation (ODD) from the U.S.

1 year ago - 24/7 Wall Street

About PRQR

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical... [Read more...]

Industry
Biotechnology
IPO Date
Sep 18, 2014
CEO
Daniel De Boer
Employees
150
Stock Exchange
NASDAQ
Ticker Symbol
PRQR
Full Company Profile

Financial Performance

In 2020, PRQR's revenue was 9.45 million, an increase of 388.98% compared to the previous year's 1.93 million. Losses were -46.61 million, -17.86% less than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for PRQR stock is "Strong Buy." The 12-month stock price forecast is 25.50, which is an increase of 260.68% from the latest price.

Price Target
$25.50
(260.68% upside)
Analyst Consensus: Strong Buy